Learn more →
Back to Expert Scholars
dermatologic-oncology / dermatologic-oncologyMelanoma Adjuvant Therapy

Alexander Eggermont

亚历山大·埃格蒙特

MD, PhD

🏢Princess Máxima Center / Institut Gustave Roussy(玛克西玛公主中心/古斯塔夫·鲁西研究所)🌐Netherlands

Chief Scientific Officer, Princess Máxima Center; Professor of Oncology玛克西玛公主中心首席科学官;肿瘤学教授

90
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Alexander Eggermont is a globally renowned melanoma expert who led EORTC trials defining adjuvant therapy standards. As former director of Institut Gustave Roussy, he pioneered adjuvant ipilimumab and pembrolizumab trials for resected high-risk melanoma, and has championed European cancer research infrastructure.

Share:

🧪Research Fields 研究领域

Dermatologic Oncology皮肤肿瘤学
Melanoma黑色素瘤
Adjuvant Therapy辅助治疗
Surgical Oncology外科肿瘤学

🎓Key Contributions 主要贡献

Melanoma Adjuvant Therapy

Led EORTC 18071 and 1325 trials establishing adjuvant ipilimumab and pembrolizumab as standard of care for resected stage III melanoma, significantly reducing recurrence risk.

Isolated Limb Perfusion

Advanced isolated limb perfusion with TNF-alpha and melphalan for unresectable limb melanomas, achieving high response rates and limb preservation.

European Cancer Research Leadership

Led Institut Gustave Roussy as director general, transforming it into a top-ranked European cancer center and championing multinational cancer research collaborations.

Representative Works 代表性著作

[1]

Adjuvant Ipilimumab versus Placebo after Complete Resection of High-Risk Stage III Melanoma (EORTC 18071)

New England Journal of Medicine (2015)

Established adjuvant ipilimumab as first immune checkpoint inhibitor to improve recurrence-free survival in resected high-risk melanoma.

[2]

Pembrolizumab versus Placebo as Adjuvant Therapy in Resected Stage III Melanoma (EORTC 1325)

New England Journal of Medicine (2018)

Demonstrated superior recurrence-free survival with adjuvant pembrolizumab over placebo, supporting its FDA approval in the adjuvant setting.

[3]

Ulceration and Stage Are Predictive of Interferon Efficacy in Melanoma

Journal of Clinical Oncology (2012)

Identified tumor ulceration as a biomarker predicting interferon adjuvant benefit, enabling patient selection for melanoma adjuvant treatment.

🏆Awards & Recognition 奖项与荣誉

🏆ESMO Lifetime Achievement Award in Oncology
🏆Society for Melanoma Research Founders Award
🏆EORTC Distinguished Member Award
🏆Netherlands Cancer Institute Research Excellence Prize

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 亚历山大·埃格蒙特 的研究动态

Follow Alexander Eggermont's research updates

留下邮箱,当我们发布与 Alexander Eggermont(Princess Máxima Center / Institut Gustave Roussy)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment